Ziemiańska Klaudia, Kopczyński Janusz, Kowalska Aldona
Department of Endocrinology, Holycross Cancer Centre, Kielce, Poland.
Department of Surgical Pathology, Holycross Cancer Centre, Kielce, Poland.
Contemp Oncol (Pozn). 2016;20(6):491-495. doi: 10.5114/wo.2016.65611. Epub 2017 Jan 12.
Fine-needle aspiration biopsy (FNAB) is the most accurate and cost-effective method to evaluate the risk of malignancy of thyroid nodules, but approximately 1-24% of FNABs generate a nondiagnostic result (ND-FNAB). The aim of this study was to determine the predictive factors of a repeated nondiagnostic result of FNAB.
A total of 4018 FNABs performed in a territorial referral centre were analysed, of which 288 (7.17%) were nondiagnostic. Medical records were available for 245 biopsies performed in 228 patients. The retrospective analysis of factors that may influence a repeat ND-FNAB, including demographic, clinical and ultrasound characteristics, was performed.
A repeat FNAB was performed in 159 nodules giving a diagnostic result in 79.2% of cases. The time between the biopsies ranged from 1 to 611 days (mean 154.4, median 119). The timing of a repeat FNAB did not significantly alter the diagnostic output ( = 0.29). In the univariate analysis, significant predictors of a repeat ND-FNAB were older patient age ( = 0.02), L-thyroxine supplementation ( = 0.05), and a history of I therapy ( < 0.0001). In the multivariate analysis, only a history of I therapy was a statistically significant risk factor for a repeat ND-FNAB ( = 0.002).
Patients with a history of I therapy and ND-FNAB should undergo periodic ultrasonographic assessment rather than a repeat biopsy. The interval between repeated FNABs recommended by guidelines does not affect the diagnostic output.
细针穿刺活检(FNAB)是评估甲状腺结节恶性风险最准确且最具成本效益的方法,但约1%-24%的FNAB会产生非诊断性结果(ND-FNAB)。本研究的目的是确定FNAB重复出现非诊断性结果的预测因素。
对一家区域转诊中心进行的4018例FNAB进行了分析,其中288例(7.17%)为非诊断性。有228例患者进行的245例活检的病历资料。对可能影响重复ND-FNAB的因素进行了回顾性分析,包括人口统计学、临床和超声特征。
对159个结节进行了重复FNAB,79.2%的病例得出了诊断结果。两次活检之间的时间间隔为1至611天(平均154.4天,中位数119天)。重复FNAB的时间安排并未显著改变诊断结果(P = 0.29)。在单因素分析中,重复ND-FNAB的显著预测因素为患者年龄较大(P = 0.02)、补充左旋甲状腺素(P = 0.05)以及有碘治疗史(P < 0.0001)。在多因素分析中,只有碘治疗史是重复ND-FNAB的统计学显著危险因素(P = 0.002)。
有碘治疗史且FNAB为ND-FNAB的患者应接受定期超声评估,而非重复活检。指南推荐的重复FNAB之间的间隔时间并不影响诊断结果。